Background: Investigations involving biopsies of human cardiac tissue often assume that myocardial samples from a specific location are representative of the entire heart. Hypothesis: There are significant regional differences in gene expression in the heart. Methods: We used two models. In the first model, seven whole human hearts were cut in 1-cm slices from apex to base and 11 distinct regions were sampled. Full thickness left ventricular tissue was further subdivided equally into an inner, outer, and middle region. In the second model, hearts were removed from adult Sprague-Dawley rats and were divided into 4 regions. Using species-specific quantitative reverse transcriptase-polymerase chain reaction, we measured transcript levels of myosin heavy chain β (MHC-β), glucose transporter 1 (GLUT 1), and atrial natriuretic factor (ANF) in tissue samples from both models. Results: In human heart, there were significant differences in transcript levels between regions. The following patterns could be recognized among the seven hearts. ANF expression was highest in the subendocardial region. MHC-β and GLUT 1 transcript levels were higher in the right ventricle than the left ventricle. As expected, ANF transcript levels were highest in the atria, where MHC-β and GLUT 1 expression was low. Analogous to the human studies, MHC-β and GLUT 1 transcript levels were low in rat atria as compared to ventricles. In rat heart, MHC-β expression was higher in the left ventricle than the right ventricle while GLUT 1 expression was not significantly different between ventricles. Conclusion: Despite the large variability in transcript levels among different regions in human hearts, certain patterns in gene expression emerged suggesting that different anatomical regions of the heart also differ in respect to gene expression.

Keywords:
Regional differences, Gene expression, Heart, Myosin heavy chain β, Atrial natriuretic factor, Glucose transporter 1, Heterogeneity
1.
Eisenberg B, Edwards J, Zack R: Transmural distribution of isomyosin in rabbit ventricle during maturation examined by immunofluorescence and staining for calcium activated adenosine triphosphate. Circ Res 1985;56:548–555.
2.
Lukas A, Antzelavitch C: Differences in electrophysiological response of canine ventricular epicardium and endocardium in response to ischemia. Role of the transient outward current. Circulation 1993;88:2903–2915.
3.
Hinton R, Hebbar L, Cox M, Mukherjee R, Joshi J, Crawford FJ, Spinale F: Left ventricular regional myocyte contractility in normal and heart failure states. J Mol Cell Cardiol 1997;29:1939–1946.
4.
Kuribayashi T, Furkawa K, Katsume H, Ijichi H, Ibata Y: Regional differences of myocyte hypertrophy and three-dimensional deformation of the heart. Am J Cardiol 1986;250:H378–388.
5.
Dosch J, Szwerc M, Lin J, Magovern J, Edwards J: Pressure overload induces heterologous expression of the atrial natriuretic factor (ANF) gene. IUBMB Life 2001;52:315–319.
6.
Campbell S, Gerdes A: Regional changes in myocyte size during the reversal of thyroid-induced cardiac hypertrophy. J Mol Cell Cardiol 1988;5:379–387.
7.
Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJA, Taegtmeyer H: Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 1998;4:1269–1275.
8.
Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H: Metabolic gene expression in fetal and failing human heart. Circulation 2001;104:2923–2931.
9.
Razeghi P, Young ME, Abbasi S, Taegtmeyer H: Hypoxia in vivo decreases peroxisome proliferator-activated receptor alpha-regulated gene expression in rat heart. Biochem Biophys Res Commun 2001;287:5–10.
10.
Young ME, Razeghi P, Cedars AM, Guthrie PH, Taegtmeyer H: Intrinsic diurnal variations in cardiac metabolism and contractile function. Circ Res 2001;89:1199–1208.
11.
Razeghi P, Myers T, Frazier O, Taegtmeyer H: Reverse remodeling of the failing human heart with mechanical unloading. Emerging concepts and unanswered questions. Cardiology 2002;98:167–174.
12.
Hansson M, Kjorell U, Forsgren S: Increased immunoexpression of atrial natriuretic peptide in the heart conduction system of the rat after cardiac sympathectomy. J Mol Cell Cardiol 1998;30:2047–2057.
13.
Hittinger L, Shannon R, Kohin S, Manders W, Kelly P, Vatner S: Exercise-induced subendocardial dysfunction in dogs with left ventricular hypertrophy. Circ Res 1990;66:329–343.
14.
Miyata S, Minobe W, Bristow M, Leinwand L: Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000;86:386–390.
15.
Bugaisky L, Gupta M, Gupta M, Zack R: Cellular and molecular mechanisms of cardiac hypertrophy; in Fozard H, Haber E, Katz A, Jennings R, Morgan HE (eds): The Heart and Cardiovascular System. New York, Raven Press, 1986, pp 1621–1640.
16.
Razeghi P, Essop MF, Huss J, Abbasi S, Manga N, Taegtmeyer H: Hypoxia-induced switches of myosin heavy chain iso-gene expression in rat heart. Biochem Biophys Res Commun 2003;303:1024–1027.
17.
Grossman W: Appendix: Normal values; in Cardiac Catheterization and Angiography, ed 1. Philadelphia, Lea & Febiger, 1978, p 329.
18.
King R, Bassingthwaighte J, Hales J, Rowell L: Stability of heterogeneity of myocardial blood flow in normal awake baboons. Circ Res 1985;57:285–295.
19.
Depre C, Vanoverschelde JLJ, Taegtmeyer H: Glucose for the heart. Circulation 1999;99:578–588.
20.
Caldwell J, Martin G, Raymond G, Bassingthwaighte J: Regional myocardial flow and capillary permeability-surface area products are nearly proportional. Am J Cardiol 1994;267:H654–H666.
21.
Bassingthwaighte J, Li Z: Heterogeneities in myocardial flow and metabolism: Exacerbation with abnormal excitation. Am J Cardiol 1999;83:7H–12H.
22.
Olsen E: Ultrastructure of the myocardium; in The Pathology of the Heart, 2 ed. London, Macmillan Press, 1980, p 30.
23.
Tan F, Moravec C, Li J, Apperson-Hansen C, McCarthy P, Young J, Bond M: The gene expression fingerprint of human heart failure. Proc Natl Aad Sci USA 2002;99:11387–11392.
24.
Blaxall B, Tschannen-Moran B, Milano C, Koch W: Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 2003;41:1096–1106.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.